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Administration of defined 
microbiota is protective in a 
murine Salmonella infection model
Sarah-Lynn E. Martz1, Julie A. K. McDonald1, Jun Sun2, Yong-guo Zhang2, Gregory B. Gloor3, 
Curtis Noordhof1, Shu-Mei He1, Teklu K. Gerbaba1, Michael Blennerhassett1, 
David J. Hurlbut4, Emma Allen-Vercoe5, Erika C. Claud6 & Elaine O. Petrof1
Salmonella typhimurium is a major cause of diarrhea and causes significant morbidity and mortality 
worldwide, and perturbations of the gut microbiota are known to increase susceptibility to enteric 
infections. The purpose of this study was to investigate whether a Microbial Ecosystem Therapeutic 
(MET-1) consisting of 33 bacterial strains, isolated from human stool and previously used to cure 
patients with recurrent Clostridium difficile infection, could also protect against S. typhimurium 
disease. C57BL/6 mice were pretreated with streptomycin prior to receiving MET-1 or control, 
then gavaged with S. typhimurium. Weight loss, serum cytokine levels, and S. typhimurium splenic 
translocation were measured. NF-κB nuclear staining, neutrophil accumulation, and localization 
of tight junction proteins (claudin-1, ZO-1) were visualized by immunofluorescence. Infected mice 
receiving MET-1 lost less weight, had reduced serum cytokines, reduced NF-κB nuclear staining, and 
decreased neutrophil infiltration in the cecum. MET-1 also preserved cecum tight junction protein 
expression, and reduced S. typhimurium translocation to the spleen. Notably, MET-1 did not decrease 
CFUs of Salmonella in the intestine. MET-1 may attenuate systemic infection by preserving tight 
junctions, thereby inhibiting S. typhimurium from gaining access to the systemic circulation. We 
conclude that MET-1 may be protective against enteric infections besides C. difficile infection.
The commensal bacteria of the gastrointestinal (GI) tract play an important role in maintaining nor-
mal barrier function and intestinal homeostasis1–3, and in protecting against pathogenic infections4. 
In addition to protecting the host from colonization by newly ingested microorganisms (colonization 
resistance), these microbes have direct effects on host inflammatory pathways and barrier function2,3,5. 
Shifts in the composition of the gut microbiota resulting in an imbalance (‘dysbiosis’) may affect normal 
function and contribute to diseases such as irritable bowel syndrome6,7, inflammatory bowel disease8,9, 
obesity10,11, and diabetes12–14.
Dysbiosis can also increase susceptibility to enteric infections15,16. Salmonella enterica serovar 
Typhimurium (S. typhimurium) is an important human pathogen and major cause of diarrhea, causing 
over 93.8 million cases of gastroenteritis and 155,000 deaths per year17. Prior antibiotic use has been 
linked to Salmonella infection in humans, and pre-exposure to antibiotics, particularly within two weeks 
prior to Salmonella infection, increases the risk of invasive non-typhoidal Salmonella disease in previously 
healthy children18,19. Animal studies of S. typhimurium infection suggest that the composition of the gut 
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microbiota is important in protection4,20. Mice given the antibiotic streptomycin prior to S. typhimurium 
ingestion develop acute inflammation of the gastrointestinal (GI) tract with weight loss, diarrhea, and 
tissue inflammation localized to the cecum, as well as systemic inflammation and extra-intestinal spread 
of infection to other tissues (e.g. spleen) at later time points21,22. Moreover, S. typhimurium-infected 
mice colonized with a less diverse defined minimal microbiota composed of 8 bacterial species (Altered 
Schaedler Flora) were colonized by S. typhimurium at high levels (108 CFU/g) and elicited pronounced 
enteropathogenesis by two days post-infection4.
Despite growing recognition that the microbiota plays an important role in protection against enteric 
infections, the underlying mechanisms remain unclear. We have developed a Microbial Ecosystem 
Therapeutic (MET-1) which has been used previously to cure recurrent Clostridium difficile disease in 
humans23. MET-1 is a defined, gut-derived microbial ecosystem of 33 bacteria cultured from the feces 
of a healthy human volunteer. As with S. typhimurium, Clostridium difficile disease is also associated 
with prior antibiotic exposure. The present study sought to expand our understanding of the func-
tion of MET-1 by investigating whether pretreatment with MET-1 could protect against disease in an 
antibiotic-associated murine model of S. typhimurium infection. We hypothesized that MET-1 would 
attenuate S. typhimurium infection through effects on the host barrier function, as well as on the path-
ogen itself.
Results
To demonstrate the protective effect of MET-1, we used the S. typhimurium colitis model in which 
C57BL/6 mice were gavaged with 20 mg of streptomycin following a 4 hour fast then after an additional 
18 hours were gavaged with MET-1, or vehicle control (VC). Four hours later, mice were gavaged with 
either S. typhimurium (“infected”) or phosphate-buffered saline (“uninfected”). Mice were euthanized 
48 hours later and samples (tissues and blood) collected for analysis. (Note: in the figures, VC indicates 
mice that have been treated with vehicle control and streptomycin).
MET-1 attenuates weight loss in Salmonella typhimurium-infected mice. To determine 
whether MET-1 administration could confer protection against S. typhimurium infection, we first 
measured mouse body weight daily as a general indicator of the overall health of each animal21. S. 
typhimurium-infected mice (VC + S. Tm. mice) lost significant weight compared to uninfected controls 
(Fig. 1a). However, infected mice receiving MET-1 lost significantly less weight than mice gavaged with 
vehicle control (− 3.50% vs. − 6.83%, respectively; p < 0.05). Mice not infected with S. typhimurium 
demonstrated normal weight gain.
MET-1 inhibits Salmonella typhimurium growth in vitro but not in the intestine. Studies 
showing that the microbiota can inhibit growth of pathogens4,24 suggest that microbe-to-microbe inter-
actions might decrease the burden of Salmonella in infected animals receiving MET-1. In vitro time kill 
assays of S. typhimurium with MET-1 indicated that MET-1 was able to inhibit growth of S. typhimurium, 
although MET-1 was unable to completely kill S. typhimurium at the concentrations tested (Fig. 2a). In 
contrast, in vivo we found no evidence that MET-1 + S. Tm. mice had a lower colonic pathogen burden 
compared to VC + S. Tm. mice (Fig.  2b). Similar results were noted in the stool (p > 0.05, data not 
shown). Analysis of mouse stool by 16S rRNA gene sequencing of samples taken 48 hours post-infection 
comparing the data from 5 separate experiments run several weeks apart showed clustering of samples 
was not based on the different groups the starting microbiota in each group had little effect on the 
Figure 1. MET-1 attenuated systemic markers of disease in S. typhimurium-infected mice. (a) MET-1 
attenuated weight loss in S. typhimurium infected mice. Following oral infection with S. typhimurium, 
mice were weighed daily and the percent change in weight from 0 to 48 hours is shown. VC = uninfected 
mice pretreated with vehicle control, n = 16; MET-1 = uninfected mice pretreated with MET-1, n = 16; 
VC + S. Tm. = S. typhimurium-infected mice pretreated with vehicle control, n = 18; MET-1 + S. Tm. = S. 
typhimurium-infected mice pretreated with MET-1, n = 18. Data were analyzed with a 2-way ANOVA using 
Bonferroni correction (*p < 0.05 at 48 hours), NS = not significant.
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course of treatment (Figure S1). Therefore, it is unlikely that direct killing of S. typhimurium by MET-1 
is involved in either decreased systemic inflammation or decreased pathogen translocation.
MET-1 did not decrease intracellular invasion of intestinal epithelial cells by Salmonella typh-
imurium. A commonly described mechanism whereby S. typhimurium causes infection involves active 
invasion of host cells25. This mechanism is independent of tight junction protein function and involves 
invasion of host cells via the Type III Secretion System (TTSS) of S. typhimurium to inject bacterial 
effector proteins, ultimately leading to internalization of the bacteria into the host cell25. Although major 
growth inhibition of Salmonella by MET-1 was not observed in Fig. 2, it has been reported that Clostridial 
species present in the fecal microbiota can inhibit the invasion virulence properties of Salmonella typh-
imurium26. To determine whether MET-1 could protect against inhibition of host cell invasion by S. 
typhimurium, or otherwise affect the invasive virulence capacity of S. typhimurium, we used an in vitro 
cell culture gentamicin-based invasion assay to determine the effect of MET-1 pretreatment on the sus-
ceptibility of Caco-2 intestinal epithelial cells to bacterial invasion by S. typhimurium. No differences 
were noted in the CFU/mL of intracellular S. typhimurium in either the MET-1 or saline groups treated 
with S. typhimurium (p > 0.05), indicating that bacterial invasion of intestinal epithelial cells was not 
prevented by MET-1 pretreatment and MET-1 did not result in statistically lower counts of Salmonella 
bacteria in this assay (Fig. 3). The controls of uninfected cell monolayer pretreated with saline, MET-1, 
or heat-killed S. typhimurium plus MET-1 did not result in any bacterial growth. These data suggest that 
MET-1 does not significantly affect the virulence or invasive capacity of S. typhimurium.
MET-1 reduced systemic spread of infection. Since the ability of S. typhimurium to translocate 
from the gut and cause metastatic infection is well described21, we sought to determine whether MET-1 
would affect the ability of S. typhimurium to disseminate to other organs. Quantification of S. typhimu-
rium in the spleen was determined by measuring the number of CFU/g of tissue, and bacterial speciation 
was confirmed by PCR. MET-1 + S. Tm mice had significantly lower S. typhimurium counts within the 
spleen compared with VC + S. Tm. mice (Fig. 4), indicating that MET-1 administration attenuated the 
ability of S. typhimurium to gain access to the systemic circulation. None of the uninfected mice had S. 
typhimurium present in the spleen.
MET-1 attenuates the increase in serum cytokine levels caused by Salmonella typhimurium 
infection. We next investigated whether MET-1 might attenuate the increase in systemic cytokine 
levels that occur after oral S. typhimurium infection27. By forty-eight hours, significant differences were 
seen for TNF-α , IL-1β , IL-12 p40, IL-12 p70, GM-CSF, eotaxin, MIP-1β and MCP-1 (Fig. 5a). All unin-
fected mice (VC mice and MET-1 mice) had similar levels of serum cytokines (p > 0.05, data not shown), 
while addition of MET-1 significantly reduced circulating levels of chemoattractants and inflammatory 
cytokines that are normally elevated in S. typhimurium infection. Chemoattractants for immune cells, 
particularly neutrophils28, were found at higher levels in the systemic circulation of the VC + S. Tm. mice 
compared to MET-1 + S. Tm. mice (Fig. 5a), suggesting that a key aspect of MET-1 action might include 
modulation of neutrophil mobilization.
Figure 2. MET-1 inhibited S. typhimurium in vitro but did not inhibit its growth in vivo. (a) MET-1 
(1:2, 1:100 and 1:300 dilutions) was incubated with S. typhimurium (S. Tm.), aliquots were withdrawn at 
times indicated, plated, counted, and plotted as log10 CFU. MET-1 inhibited the growth of S. Tm. relative to 
the S. Tm. control, although MET-1 was unable to completely kill S. Tm. even at a high (1:2) concentration. 
(b) Colons were harvested 48 hours after S. Tm. infection, homogenized in sterile PBS, and plated. Infected 
mice pretreated with MET-1 (MET-1 + S. Tm.) showed no significant reduction of S. Tm. counts in the 
colon (p > 0.05) compared to mice pretreated with vehicle control (VC + S. Tm.). S. Tm. was not detected 
in the colon of uninfected mice. Data were analyzed using a 1-way ANOVA with Bonferroni correction. 
VC = uninfected mice pretreated with vehicle control, n = 18; MET-1 = uninfected mice pretreated with 
MET-1, n = 18; VC + S. Tm. = S. typhimurium-infected mice pretreated with vehicle control, n = 22; 
MET-1 + S. Tm. = S. typhimurium-infected mice pretreated with MET-1, n = 21.
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MET-1 attenuates local TNF-α expression induced by Salmonella typhimurium infection in 
cecum. To determine whether MET-1 also affected local pro-inflammatory cytokine expression in the 
intestine, we next looked at the expression of TNF-α in the cecum using quantitative real-time PCR. 
TNF-α is a key mediator of inflammation in the early stages of Salmonella infection and acts by recruit-
ing neutrophils to the site of infection29,30. It was found that the expression of TNF-α was significantly 
increased in VC + S. Tm. mice compared to uninfected controls (Fig.  5b). However, MET-1 effectively 
reduced TNF-α expression in the MET-1 + S. Tm. treatment group. The addition of MET-1 alone had 
no significant effect on TNF-α expression.
MET-1 attenuates local neutrophil infiltration in cecum induced by Salmonella typhimu-
rium infection. Localized responses of the immune system were examined in the intestinal mucosa, 
where infection with S. typhimurium causes an influx of neutrophils31. At 48 hours post-infection, 
Figure 3. MET-1 pre-treatment does not prevent S. typhimurium intracellular invasion of Caco-2 
epithelial cells. Live (or heat-killed) S. typhimurium were added to Caco-2 cell monolayers at an MOI 
of 100:1 and incubated for 1 hour. Extracellular bacteria were then killed by the addition of gentamicin 
(100 μ g/mL). One hour later, Caco-2 cells were lysed and intracellular bacteria were enumerated using 
serial dilutions plated on MacConkey agar plates containing 100 μ g/mL streptomycin. There were no 
significant differences between S. typhimurium-infected cells pretreated with MET-1 (MET-1 + Sal) or 
saline (Saline + Sal) (p > 0.05). No bacterial growth was seen in cell monolayers treated with saline only 
(Saline), MET-1 only (MET-1), heat-killed S. typhimurium only (Saline + HK Sal) or MET-1 pretreated cell 
monolayers treated with heat-killed S. typhimurium (MET-1 + HK Sal). Data were analyzed using a 1-way 
ANOVA with Bonferroni correction, n = 3, (p > 0.05) NS = not significant.
Figure 4. Translocation of S. typhimurium to the spleen was reduced in MET-1 pretreated mice. 
Spleens were harvested 48 hours after S. typhimurium infection, weighed, and homogenized in 1 mL PBS. 
Serial dilutions were plated on MacConkey agar plates containing 100 μ g/mL streptomycin. Plates were 
incubated at 37 °C for 24 hrs, and the resulting colonies were counted. Infected mice pretreated with MET-1 
(MET-1 + S. Tm., n = 13) had reduced S. typhimurium counts in the spleen (*p < 0.05) compared to mice 
pretreated with vehicle control (VC + S. Tm., n = 12). S. typhimurium was not detected in the tissues of 
uninfected mice pretreated with vehicle control (VC, n = 12) or MET-1 (n = 12). Data were analyzed using a 
1-way ANOVA with Bonferroni correction.
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immunocytochemistry showed increased staining for cecum MPO, a principal marker of neutrophils32, 
which was significantly reduced by treatment with MET-1 (Fig.  6a). Image analysis and quantification 
showed a 5-fold reduction in MPO staining in MET-1 + S. Tm. mice versus VC + S. Tm. mice (Fig. 6b). In 
addition, the nuclear localization of NF-κ B, a key transcription factor and regulator of pro-inflammatory 
pathways that translocates to the nucleus when activated, was found to be reduced (Fig. 6c). The addition 
of MET-1 alone had no significant effect on either nuclear NF-κ B or neutrophil accumulation in the ceca 
of uninfected mice.
MET-1 does not enhance intestinal mucin production in cecum. Since MUC2 has been pro-
posed as an important host defense mechanism against S. typhimurium33,34, mucin production was exam-
ined in VC + S. Tm. mice and MET-1 + S. Tm. mice. Alcian blue staining showed that MET-1 + S. Tm. 
mice did not have increased staining (Fig. 7a) or goblet cell counts (Fig. 7b) compared to VC + S. Tm. 
mice. Moreover, no differences in MUC2 immunostaining were noted in MET-1 + S. Tm. mice compared 
to VC + S. Tm. mice (Fig. 7c,d). These data argue against MET-1-induced differences in intestinal mucus 
as a likely mechanism for conferring systemic protection against S. typhimurium.
MET-1 attenuates disruption of tight junction proteins in cecum caused by Salmonella typh-
imurium. S. typhimurium causes compromise of the intestinal epithelial barrier via disruption of tight 
junction proteins including ZO-1 and claudin 125,35. Bacterial entry through the paracellular route, in 
addition to direct cellular invasion35, is thought to be an important contributor to dissemination of 
Figure 5. Pro-inflammatory cytokine levels were reduced in S. typhimurium-infected mice pretreated 
with MET-1. (a) Serum cytokine levels were measured 48 hours post-infection using a Bio-Plex Pro 
mouse cytokine magnetic bead kit. Of the cytokines measured, TNF-α , IL-1β , IL-12p40, IL-12p70, GM-
CSF, eotaxin, MIP-1β , and MCP-1 were all significantly reduced in infected mice pretreated with MET-1 
(MET-1 + S. Tm.) compared to infected mice pretreated with vehicle control (VC + S. Tm.). There were 
no significant differences in cytokine concentrations between uninfected mice pretreated with MET-1 or 
vehicle control (data not shown). Data were analyzed using a 1-way ANOVA with Bonferroni correction, 
n = 7 for each group (*p < 0.05, **p < 0.01, ***p < 0.001). (b) Cecal TNF-α expression was attenuated in S. 
typhimurium-infected mice pretreated with MET-1, as determined by quantitative RT-PCR (qRT-PCR) was 
performed in triplicate. The relative TNF-α expression was normalized to an endogenous control (GAPDH 
expression). The relative expression of TNF-α was attenuated in infected mice pretreated with MET-1 
(MET-1 + S. Tm.) compared to infected mice pretreated with vehicle control (VC + S. Tm.). The level of 
expression in MET-1 + S. Tm. mice was not significantly different from uninfected mice pretreated with 
vehicle control (VC) or MET-1. Data were analyzed using a 1-way ANOVA with Newman-Keuls multiple 
comparison test, n = 4 for each group (*p < 0.05).
www.nature.com/scientificreports/
6Scientific RepoRts | 5:16094 | DOi: 10.1038/srep16094
infection36. In uninfected mouse ceca (VC mice or MET-1 mice), ZO-1 immunofluorescence was abun-
dant in epithelial cells (Fig.  8a). In contrast, VC + S. Tm. mice had loss of ZO-1 membrane staining 
which was preserved in MET-1 + S. Tm. mice. Western blot analysis of the membrane-associated fraction 
of intestinal lysates demonstrated increased expression of ZO-1 in MET-1 + S. Tm. mice compared to 
VC + S. Tm. mice (Fig. 8b), indicating preserved expression of ZO-1 in MET-1 + S. Tm. mice.
Figure 6.  MET-1 attenuates local neutrophil infiltration induced by S. typhimurium infection in cecum (a) 
Representative images of myeloperoxidase (MPO) immunofluorescence staining for neutrophils (green) in 
ceca. The area in the box (left) is displayed at a higher magnification in the panels on the right. Nucleic acid 
was stained using Hoechst (blue). S. typhimurium-infected mice pretreated with vehicle control (VC + S. 
Tm.) had more abundant immunostaining in the ceca compared to uninfected controls (VC), and was 
significantly reduced in the ceca of infected mice pretreated with MET-1 (MET-1 + S. Tm. mice). No MPO 
staining was noted in secondary antibody control slides for each group (not shown). (b) Quantification of 
MPO immunostaining, shown by the ratio of MPO (green immunofluorescence) staining to number of 
cells (blue nuclei). Data analyzed using 1-way ANOVA with Bonferroni correction, ***p < 0.001. n = 4 for 
VC, MET-1, and MET-1 + S. Tm. groups, n = 3 for VC + S. Tm. group. 3–5 fields of view per section. (c) 
Representative images of NF-κ B P65 immunofluorescence staining (red) in ceca. The area in the box (left) 
is displayed at a higher magnification in the panels on the right. Nuclei were stained using Hoechst (blue). 
VC + S. Tm. mice had significantly increased NFκ B P65 translocation (pink immunofluorescence) into the 
nucleus compared with MET-1 + S. Tm. mice. Secondary antibody control slides for each group showed 
no NFκ B P65 staining (images not shown). (d) Ratio of NF-κ B P65 nuclear staining to the total number 
of epithelial cells per high power field. The percentage of NF-κ B P65 stained cells was normalized to the 
VC + S. Tm. group. Images taken at 400× magnification from at least two sections per cecum tissue. At 
least five non-adjacent images were taken for each section. Images were quantified from two independent 
experiments and each experiment had at least three mice per group. Total number of mice for each 
treatment group for two independent experiments was 6- to 9. Data were analyzed using ANOVA with 
Bonferroni correction, (***p < 0.001 and *p < 0.05).
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Similarly, VC + S. Tm. mice showed reduced staining intensity, as well as disaggregation and clumping 
of epithelial claudin-1 immunofluorescence. This outcome was markedly attenuated in MET-1 + S. Tm. 
Mice (Fig.  8c,d). Additionally, Western blot analysis showed that MET-1 + S. Tm. mice had increased 
claudin-1 expression in the membrane fractions compared to VC + S. Tm. mice (Fig. 8d), showing that 
administration of MET-1 in S. typhimurium-infected mice preserved claudin-1 expression.
Discussion
This study sought to address whether a defined gut microbial community that has been previously used 
to cure C. difficile infection23 may also act to protect against S. typhimurium, another gut pathogen and 
important cause of diarrheal illness in humans associated with antibiotic use and dysbiosis. We hypoth-
esized that MET-1 would attenuate S. typhimurium infection through both antagonistic effects on the 
pathogen as well as effects on the host. However, we found that MET-1 had little effect on pathogen 
Figure 7. MET-1 did not enhance intestinal mucin production in ceca of S. typhimurium- infected 
mice. (a) Alcian blue staining (blue) of ceca fixed in 10% formalin were counterstained with nuclear red 
fast solution (red). (b) Goblet cells were enumerated from 10 random high-powered field views (400× 
magnification) spanning from muscularis mucosa to surface epithelium on Alcian blue stained sections. 
Infected mice pretreated with vehicle control (VC + S. Tm.) had less mucin staining than uninfected mice 
pretreated with vehicle control (VC + S. Tm.). However, there was no statistically significant difference 
between infected mice pretreated with MET-1 (MET-1 + S. Tm.) and vehicle control (VC + S. Tm.). (c) 
MUC2 immunofluorescence staining (green) in ceca fixed in Methanol-Carnoy’s solution. Nucleic acid was 
stained using DAPI (blue). Uninfected mice pretreated with VC or MET-1 had similar localization of MUC2 
staining that differed from VC + S. Tm. mice. Again, MUC2 staining in MET-1 + S. Tm. mice more closely 
resembled VC + S. Tm. mice than uninfected controls. Quantification shown in (d). Data were analyzed 
using a 1-way ANOVA with Bonferroni correction. n = 3, (**p < 0.01, ***p < 0.001) NS = not significant.
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Figure 8. MET-1 pretreatment prevented the disruption of ZO-1 and claudin-1 cellular localization 
in the cecum caused by S. typhimurium. (a) ZO-1 immunofluorescence staining (green) in ceca fixed in 
10% formalin (400× magnification). Nuclei were stained using Hoechst (blue). White arrows indicate green 
staining of ZO-1 protein at the membrane of intestinal epithelial cells. VC = uninfected mice pretreated with 
vehicle control; MET-1 = uninfected mice pretreated with MET-1; VC + S. Tm. = S. typhimurium-infected 
mice pretreated with vehicle control; MET-1 + S. Tm. = S. typhimurium-infected mice pretreated with MET-
1. VC + S. Tm. mice had a loss of ZO-1 membrane staining that was attenuated in MET-1 + S. Tm. mice.  
(b) Expression of ZO-1 measured by Western blot analysis (S, Triton X-soluble fraction; I, Triton X-insoluble 
fraction, sample blot shown in top right of panel). Consistent with data in panel (a), densitometric values 
calculated for the ratio of ZO-1 to β -actin showed that MET-1 + S. Tm. mice had increased expression of 
ZO-1 in insoluble fractions compared to VC + S. Tm. mice. Data were analyzed using a 1-way ANOVA 
with Bonferroni correction (*p < 0.05). n = 5 mice for VC + S. Tm., n = 4 for MET-1 + S. Tm. (c) Claudin-1 
immunofluorescence staining (green) in ceca fixed in 10% formalin (400x magnification). Nucleic acid 
was stained using Hoechst (blue). VC + S. Tm. mice displayed disaggregation and clumping of epithelial 
claudin-1 immunofluorescence, along with discontinuities in membrane staining and a reduction in staining 
intensity. This alteration in claudin-1 expression was attenuated in MET-1 + S. Tm. mice. (d) Expression of 
claudin-1 was measured by Western blot analysis (S, Triton X-soluble fraction; I, Triton X-insoluble fraction, 
sample blot shown). Densitometric values were calculated for the ratio of claudin-1 to actin and showed that 
MET-1 + S. Tm. mice had increased expression of claudin-1 in insoluble fractions compared to VC + S. Tm. 
mice. Data were analyzed using a 1-way ANOVA with Bonferroni correction (**p < 0.01). n = 5 mice for 
VC + S. Tm., n = 4 for MET-1 + S. Tm.
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burden. Instead, MET-1 attenuated the systemic and localized effects of Salmonella infection and pre-
served intestinal tight junction protein expression.
MET-1 did not decrease S. typhimurium levels in the colon but systemic colonization was reduced 
in the infected animals treated with MET-1; levels of S. typhimurium in the small intestine were not 
measured, since MET-1 bacteria are derived from large intestine and are not expected to colonize the 
small intestine. However, the small intestine is a major point of Salmonella invasion and another study by 
Antunes et al. reported that fecal microbiota can inhibit the expression of invasion virulence factors by S. 
typhimurium26. In contrast to the latter report26, MET-1 did not have any effects on the ability of S. typh-
imurium to intracellularly invade intestinal epithelial cells when tested in an in vitro invasion assay. This 
may be due to the fact that the Lachnospiraceae species found by that study to be most inhibitory, such 
as C. citroniae and C. aldenense, are found within the C. clostridioforme subclade of the Lachnospiraceae 
family, and this group is not represented in MET-1. Collectively, our results indicate that MET-1 confers 
protection against S. typhimurium primarily through its effects on multiple host functions, rather than 
through direct effects on Salmonella.
MET-1 was found to have only modest inhibition of Salmonella in time-kill assays and no effect in 
vivo. The interplay between MET-1, S. typhimurium, and the host that occurs in the setting of the host 
inflammatory response to infection also likely contributes to this finding. Several studies have described 
the fitness advantage provided to facultative anaerobes in the environment of the inflamed intestine, 
replete with superoxide radicals, reactive oxygen species and reactive nitrogen species that may allow S. 
typhimurium to utilize alternate metabolic pathways and energy sources37,38. S. typhimurium has devel-
oped evolutionary strategies to utilize compounds reacting with organic sulfides and tertiary amines in 
the gut lumen as terminal electron acceptors for anaerobic respiration, thus allowing it to thrive in the 
gut under conditions of inflammation. Since MET-1 is composed primarily of anaerobic bacteria that 
cannot utilize these same metabolic pathways and carbon sources, we speculate that the inflamed milieu 
would provide favorable conditions for growth of S. typhimurium and may additionally contribute to the 
lack of MET-1 inhibition against S. typhimurium growth observed in vivo.
At the apical intestinal surface, TJ complexes between epithelial cells that involve cytoplasmic and 
membrane proteins such as claudin-1 and ZO-1 normally maintain the epithelial barrier39. By disrupting 
this, and altering the distribution of TJ proteins40 S. typhimurium can increase paracellular permeability 
and membrane “leakiness” to provide an additional route of access to the basolateral compartment35,36. 
Our data indicate that MET-1-mediated preservation of tight junction protein expression is a probable 
mechanism for the decreased systemic effects of S. typhimurium. While upregulation of mucins such 
as MUC2 by probiotic commensal bacteria has been reported34,41, we found no evidence to support a 
MET-1 effect on intestinal mucus or MUC2. We chose to focus on MUC2, since this is the main mucin 
produced by goblet cells42 however goblet cells produce other mucins that could potentially be induced 
by exposure to MET-1 and the possibility exists that other mucins or other secretory products from 
goblet cells, induced by MET-1, may exist that could contribute to host protection against Salmonella.
There was a significant reduction in the serum cytokines involved in the maturation and recruitment 
of neutrophils (GM-CSF, MCP-1 eotaxin and MIP-1β ) in infected animals that received MET-1. It is 
tempting to speculate that a MET-1-mediated decrease in the neutrophil population in the gut of infected 
MET-1 mice may have also contributed to decreased barrier disruption, since neutrophil transmigration 
across the epithelial barrier causes a breach in barrier function through release of neutrophil proteases 
such as elastase, which transiently degrade epithelial tight junctions and increase “leakiness” across the 
paracellular space43,44.
In assessing the microbiome of MET-1 treated and non-treated groups we found that some MET-1 
isolates were identical to murine microbiota sequences that pre-existed in the mice (such as the 
Parabacteroides), whereas others (Acidaminococcus intestini, Roseburia faecalis/intestinalis, Bacteroides 
ovatus, and Bifidobacterium adolescentis/longum) were unique to MET-1 and separable from what was 
originally in the mice at baseline, prior to receiving MET-1. However, limitations of the 16S rRNA gene 
profiling technique (which have been recognized in our previous human studies23) mean that it is impos-
sible to be certain that changes in the murine gut microbiota brought about by MET-1 treatment were the 
result of colonization by MET-1 components; to effectively do this would require isolation of microbes 
from the murine gut, genome sequencing of these isolates, and alignment of obtained sequences with 
MET-1 component genomes, which was beyond the scope of this work. We are currently working to 
identify unique sequence signatures in MET-1 genomes that can be used to differentiate MET-1 strains 
from others and which can be used in our future efforts to understand the nature of MET-1 component 
colonization in different hosts.
As a complex ecosystem, MET-1 has the potential to accomplish multiple core functions of the micro-
biota and to act through multiple mechanisms to protect the host. Here, a single dose of MET-1 resulted 
in improved outcomes - a potential advantage of using a defined, gut-derived microbial ecosystem acting 
through multiple mechanisms, over standard single-strain probiotics45,46. This study extends previous 
observations using defined microbial mixtures to treat recurrent C. difficile infection23,47,48. We demon-
strate here that MET-1 confers protective properties in S. typhimurium infection both through attenuated 
inflammation and preservation of tight junction proteins, providing evidence that this defined microbial 
community may be useful for the treatment of other enteric infections in addition to C. difficile infection. 
Future studies of the complex interplay between host, microbiota and pathogen will be instrumental 
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in leading to both a better understanding of gastrointestinal infectious disease and novel strategies of 
microbiota-based therapies.
Materials and Methods
Ethics statement. This study was carried out in accordance with the guidelines of the Canadian 
Council of Animal Care and was approved by Queen's University Animal Care Committee.
Bacterial culture. Salmonella enterica serovar Typhimurium SL1344 (Caliper Life Sciences, MA, 
USA), a streptomycin-resistant strain, was grown in Luria-Bertani (LB) broth (Bioshop Canada 
Inc., ON, Canada) supplemented with 100 μ g/mL streptomycin at 37 oC for 18  hours as previously 
described49.
The derivation of MET-1 (Table 1), commensal colonic bacteria from a healthy human volunteer, is 
described elsewhere23. In brief, the 33 MET-1 isolates were cultured on fastidious anaerobe agar (FAA) 
(Lab M Ltd., Lancashire, UK) with or without 5% defibrinated sheep blood (Hemostat Laboratories, 
CA, USA) under anaerobic conditions. Plates were incubated at 37 °C for 2–3 days under strict anaer-
obic conditions in a Bugbox (Ruskinn, Maine, USA). Biomass was scraped directly into pre-reduced, 
filter-sterilized 0.9% saline using microbiological loops to achieve 3.5 × 109 CFU/mL23, previously deter-
mined to approximate the relative abundance of similar species in the stool samples of healthy North 
Americans (http://www.hmpdacc.org/).
Salmonella enterica serovar Typhimurium colitis model. The S. typhimurium model of colitis21 
was initiated in 6–7 week old female C57BL/6 mice (Charles River, MA, USA). Mice were fasted for 
Higher taxonomic group Closest species matcha
Actinobacteria
Bifidobacterium adolescentis (two different 
strains)
Bifidobacterium longum (two different strains)
Collinsella aerofaciens
Bacteroidetes
Bacteroides ovatus
Parabacteroides distasonis
Firmicutes
Bacilli
Lactobacillus casei/paracasei
Lactobacillus casei
Streptococcus mitis
Clostridium cluster IV
Eubacterium desmolans
Faecalibacterium prausnitzii
Clostridium cluster VIII Clostridium cocleatum
Clostridium cluster IX
Acidaminococcus intestini
Blautia sp.
Dorea longicatena (two different strains)
Eubacterium eligens
Clostridium cluster XIVa
Eubacterium rectale (four different strains)
Eubacterium ventriosum
Lachnospira pectinoshiza
Roseburia faecalis
Roseburia intestinalis
Ruminococcus torques (two different strains)
Ruminococcus spp. (two different strains)
Clostridium cluster XV Eubacterium limosum
Proteobacteria
Escherichia coli
Raoultella sp.
Table 1.  List of cultured isolates from the healthy donor comprising the MET-1 synthetic community. 
Based on their DNA sequence identification, the MET-1 strains are represented according to their 
phylogenetic nomenclature/biological classification (http://www.arb-silva.de/projects/living-tree/)56. The 
table has the 4 major gut phyla (Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria), with the 
Firmicutes further divided into classes, for clarity. aClosest species match inferred by alignment of 16S rRNA 
sequence to GreenGenes database.
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four hours prior to oral gavage with 20 mg of streptomycin (SteriMax, ON, Canada), after which mice 
had access to food and water ad libitum. Eighteen hours later mice were gavaged with either 100 μ L of 
MET-1 (corresponding to 3.5 × 108 CFU) or vehicle control (0.9% saline). Four hours later mice were 
gavaged with 108 CFU of S. typhimurium or phosphate buffered saline (PBS). Weights were monitored 
daily and mice from each treatment group were euthanized 48 hours post-infection. Tissues and blood 
were collected for analysis as described below.
Bacterial enumeration in tissues and stool. Forty-eight hours post-infection spleens and colons 
were harvested for enumeration of S. typhimurium. Tissues were weighed, homogenized in 1 mL of 
sterile PBS, and serial dilutions of homogenates plated on MacConkey agar containing 100 μ g/mL 
streptomycin, incubated at 37 °C for 24 hours. Colonies were confirmed as S. typhimurium by PCR 
and an amplified band of the correct size on a 1% agarose gel was confirmed to be from S. typhimu-
rium50. PCR primer sequences used50 were: forward primer 5′ -AACAACGGCTCCGGTAATGA-3′ and 
reverse primer 5′ -TGACAAACTCTTGATTCTGA-3′ , targeting a putative cytoplasmic protein (310 bp 
product, STM4497) and forward primer 5′ -TTTGGCGGCGCAGGCGATTC and reverse primer 5′ 
GCCTCCGCCTCATCAATCCG (423 bp product, STM3098), targeting a putative transcriptional regu-
lator, both of which have been used to detect Salmonella species51. Cycling conditions: 95 °C for 3 min, 
(95 °C for 30 s, 58 °C for 30 s, 72 °C for 90 s) × 30; 72 °C for 5 min.
Multiplex bead assay to measure serum cytokine levels. Blood was collected via cardiac punc-
ture 48 hours post-infection and a mouse cytokine magnetic bead kit (Bio-Plex Pro Mouse Cytokine 
multiplex, Bio-Rad, CA, USA) was used to measure serum IL-1α , IL-1β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, 
IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17A, eotaxin, G-CSF, GM-CSF, INF-γ , KC, MCP-1, MIP-1α , 
MIP-1β , and TNF-α , as per the manufacturer’s instructions.
Immunohistochemistry. Immunofluorescence staining was carried out on formalin-fixed cecal tis-
sues with the exception of MUC2, where tissues were fixed in Carnoy’s fixative52. Paraffin embedded 
tissues were sectioned (4 μ m), hydrated and subjected to antigen retrieval in citric acid buffer (10 mM 
citric buffer, 2 mM EDTA, 0.05% Tween 20, pH 6.0).
For myeloperoxidase (MPO), claudin and NF-κ B P65 staining, tissues were blocked with PBS 
containing 0.3 M glycine and 0.1% Tween 20, 3% bovine serum albumin (Bioshop Canada Inc.) 
and 10% goat serum (Sigma Aldrich), for one hour at room temperature. For MUC2, tissues were 
blocked with PBS with 5% fetal bovine serum (FBS) for 1 hour at room temperature. ZO-1 tissues 
were blocked with PBS-T containing 2% bovine serum albumin and 1% goat serum for 1 hour at 
room temperature.
Sections were stained with rabbit anti-MPO (1:100, Abcam, MA, USA) or rabbit anti-claudin-1 
(1:200, Abcam), or rabbit anti-NF-κ B P65 (1:50, Santa Cruz) or rabbit anti-MUC2 (1:100 dilution, Santa 
Cruz) or 1:100 mouse anti-ZO-1 (Invitrogen), in blocking buffer over night at 4 °C. Sections were washed 
with PBS-T three times, then incubated with Alexa 488-conjugated goat anti-rabbit immunoglobulin 
G (Invitrogen, CA, USA) at a 1:500 dilution (MPO, claudin, NF-κ B, and MUC2) or 1:100 (ZO-1) in 
blocking buffer. Tissues were incubated for one hour at room temperature for MPO, claudin, NF-κ B, 
ZO-1 and two hours at room temperature for MUC2. Prolong antifade mounting media containing 
4,6-diamidino-2-phenylindole (DAPI) was used to stain nuclei (Invitrogen).
For MPO, claudin and NF-κ B, images were obtained using an Olympus BX51 microscope and 
Image-Pro Plus software (Media Cybernetics, Inc., MD, USA). MUC2 images were visualized using an 
AxioImager M.1 microscope and AxioVision software (Carl Zeiss, Oberkochen, Germany). ZO-1 images 
were obtained using a Zeiss LSM 710 Laser Scanning confocal microscope.
Images used for quantification were taken at 400× magnification from at least two non-adjacent 
sections of cecum per mouse, and 4 non-adjacent images were then used for each section to quantify. 
Images were taken from two independent experiments and each experiment had 3–4 mice per group. 
Total number of cells (determined by DAPI staining of nuclei) per view at 400× magnification was 
counted using ImagePro Plus software. An average of 700 cells (range: 540–1000 cells) was counted per 
view. The area of green fluorescence was measured using the ImagePro Plus software. The ratio of area of 
green versus total number of nuclei was used for the quantification53. Data were analyzed using a 1-way 
ANOVA with Bonferroni correction.
Alcian blue staining. Sections of mouse ceca were rehydrated, immersed in 3% acetic acid for 2 min-
utes and then stained with 1% (w/v) Alcian blue solution (8GX, Acros Organics, NJ, USA) in 3% acetic 
acid (pH 2.5) for 30 minutes. Tissues were rinsed in distilled water and counterstained with 0.1% nuclear 
fast red solution (Acros Organics) for 1 minute. All images were visualized using an Olympus BX60 
microscope and Infinity Capture software (Lumenera Corporation, ON, Canada). Goblet cells were enu-
merated from stained tissues by counting goblet cells in 10 random high-powered fields/sample (400x 
magnification) spanning muscularis mucosa to surface epithelium.
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Western blot analysis. Cecal tissues were sonicated in lysis buffer (10mM Tris, pH 7.6 containing 
5 mM MgSO4, DNAse I, RNAse A, and protease inhibitor cocktail; Roche, ON, Canada). Samples were 
incubated on ice for 20 minutes and centrifuged at 2,900 × g for 20 minutes at 4 °C. For fractionated 
samples, supernatant containing both cytosolic and membrane fractions were centrifuged at 21,000 × g 
for 45 minutes at 4 °C. The resulting supernatants comprised the soluble (S) cytosolic fractions. Pellets 
were resuspended in RIPA buffer (25 mM Tris, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deox-
ycholate, 0.1% SDS, and protease inhibitor cocktail), left on ice for 20 minutes, and centrifuged at 
15,000 × g for 20 minutes at 4 °C; the resulting supernatants comprised the insoluble (I) membrane 
fractions.
Samples of whole lysates, soluble fractions, or insoluble fractions were separated on a 12% 
SDS-PAGE gel, transferred overnight before blocking with 5% non-fat dry milk in TBST for 1 hour at 
room temperature. Membranes were then incubated with 1:1000 anti-ZO-1 (Life Technologies, ON, 
Canada), 1:1000 anti-claudin-1 (Life Technologies), or 1:10,000 anti-β -actin (Sigma Aldrich) overnight 
at 4 °C. After washing with TBS-T three times, horseradish peroxidase (HRP)-conjugated secondary 
antibodies were added (1:10,000 dilution, Cell Signaling, MA, USA) and membranes incubated for 
1 hour at room temperature. After three more washes with TBS-T, PVDF membranes were exposed to 
chemiluminescence (ECL) reagents (Thermo Fisher Scientific, MA, USA) and exposed to autoradio-
graphic film (VWR, ON, Canada) for band visualization. Protein levels were quantified by densitom-
etry using ImageJ software.
Salmonella enterica serovar Typhimurium time-kill assay. MET-1 (initially 3.5 × 109 CFU/mL) 
was co-cultured with S. typhimurium (using different dilutions of MET-1, see below) and S. typhimurium 
viable counts monitored over time. Each well contained 107 CFU S. typhimurium in Wilkins Chalgren 
broth (Bioshop Canada Inc.) The overall bacterial CFU of MET-1: S. Tm. were as follows: MET-1 1:2 
dilution = 3.5 × 109 CFU MET-1: S. typhimurium (350:1); 1:100 dilution = 7.0 × 107 CFU MET-1: S. typh-
imurium (7:1); 1:300 dilution = 2.3 × 107 CFU MET-1: S. typhimurium (2.3:1). Mixtures were incubated 
at 37 °C under anaerobic conditions (90% N2, 5% CO2, and 5% H2) for 24 hours, and 100 μ L aliquots 
withdrawn at 0, 1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours, serial diluted, and plated on MacConkey agar 
plates containing 100 μ g/mL streptomycin. Plates were incubated at 37 °C for 24 hours and colonies were 
enumerated.
Salmonella enterica serovar Typhimurium invasion assay. The effect of MET-1 pretreatment on 
the susceptibility of Caco-2 cells (ATCC HTB-37) to S. typhimurium infection was assessed using an 
invasion assay based on a previous study54. Briefly, Caco-2 cells were seeded in 12-well plates and main-
tained in Dulbecco’s minimal essential medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) (37 °C in a 5% CO2, 95% air atmosphere). Wells containing 70–90% confluent monolayers54 were 
washed in DMEM and MET-1 or saline was added to each well (10% concentration). Cells were incu-
bated at 37 °C for 1 hr, media were removed, cells were washed with PBS, and fresh media were added. 
Washed live or heat-killed (boiled for 30 min) S. typhimurium (multiplicity of infection of 100:1) or 
saline (equivalent volume) were added to each well. Cells were incubated at 37 °C for 1 hr and washed 
with PBS. Non-internalized S. typhimurium cells were killed with gentamicin (100 μ g/mL) for 1 hr at 
37 °C. Media were removed, cells were washed with PBS, and cells were treated with 0.1% Triton X-100 
and incubated for 10 minutes. CFU/mL of S. typhimurium were calculated by serial dilutions plated onto 
MacConkey agar (Difco Laboratories, Becton, Dickinson and Company, MD, USA) supplemented with 
streptomycin (100 μ g/mL).
Quantitative real-time PCR. An approximately 5 mm section of cecum tissue was immedi-
ately stored in RNAlater (Sigma Aldrich). Briefly, tissue was homogenized and RNA was extracted 
using an RNeasy Mini kit (Qiagen, ON, Canada) as per manufacturer’s instructions. RNA quality 
was assessed by absorbance at 260 nm (on a spectrophotometer) and by running on the Agilent 
2100 Bioanalyzer (Agilent Technologies, ON, Canada). RNA was treated with RNAse free DNAse 
I (Invitrogen) to eliminate genomic DNA and quantitative RT-PCR (qRT-PCR) was performed in 
triplicates using the StepOnePlusTM Real-Time PCR System (Life Technologies). qRT-PCR was run 
using q-ScriptTM One-Step SYBR Green qRT-PCR kit (Quanta Biosciences, MD, USA) in a 10 μ L 
reaction volume containing equal amounts of RNA (62 ng), 5 μ L One-Step SYBR Green Master Mix, 
0.2 μ L qScript One-Step Reverse Transcriptase, and gene specific forward (TNF-α , 200 nM; GAPDH 
50 nM) and reverse (TNF-α , 50 nM; GAPDH, 150 nM) primers. Cycling conditions were as follows: 
50 °C for 5 min, 95 °C for 2 min, (95 °C for 3 s, 60 °C for 30 s) × 40 cycles. The TNF-α and GAPDH 
primer sequences were as follows: TNF-α , forward 5′ -CCACCACGCTCTTCTGTCTA-3′ , reverse 
5′ -AGGGTCTGGGCCATAGAACT-3′ ; GAPDH, forward 5′ -CGTCCCGTAGACAAAATGGT-3, 
reverse 5′ -TTGATGGCAACAATCTCCAC-3′ . The relative expression of TNF-α normalized to the 
expression of GAPDH (endogenous control) was calculated by the comparative CT (Δ Δ CT) method55 
using the vehicle control group as a reference group and one of the vehicle control group mice as a 
reference sample.
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Statistical analysis. Results are expressed as the mean value with standard error of the mean (SEM). 
Statistical analyses were performed with GraphPad Prism version 5.0 (GraphPad Software, CA, USA). 
A two-tailed unpaired t-test, 2-way ANOVA with a Bonferroni correction, or 1-way ANOVA with 
Newman-Keuls or a Bonferroni correction was used where indicated. Statistical significance was set at 
a P value of < 0.05.
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